Jazz Pharmaceuticals (JAZZ) Financials

Jazz Pharmaceuticals’ latest quarter shows a much stronger profit profile, but with a balance sheet that remains heavily leveraged and still burdened by large intangible assets from past acquisitions.

For Q1 2026, Jazz reported revenue of $1.069 billion, up from $1.045 billion in Q2 2025 and $897.8 million in Q1 2025. The company also swung to a solid profit of $293.1 million, or $4.43 diluted EPS, compared with a loss of $718.5 million in Q2 2025 and a loss of $92.5 million in Q1 2025. That turnaround was helped by a much leaner operating expense profile and a positive contribution from operating income.

Cash generation also looks healthier. Operating cash flow in Q1 2026 was $408.2 million, up from $362.5 million in Q4 2025 and far better than the weak $88.9 million in Q2 2025. Jazz ended Q1 2026 with $1.84 billion in cash and equivalents plus $1.03 billion in short-term investments, giving it substantial liquidity. Total current assets of $4.58 billion also comfortably exceed current liabilities of $2.25 billion.

That said, the balance sheet still carries meaningful risk. Total debt remains high at roughly $5.35 billion combined short-term and long-term debt, and total liabilities were $7.33 billion versus equity of $4.53 billion. Jazz also has a very large base of $4.2 billion in intangible assets and $1.8 billion of goodwill, which means the balance sheet is still tied to prior acquisitions and could be sensitive to impairment risk if growth weakens.

• Revenue is trending higher versus the prior several quarters, with Q1 2026 sales of $1.069 billion above both Q1 and Q2 2025.
• Profitability improved sharply, with Q1 2026 net income of $293.1 million versus a loss in Q2 2025 and modest profit in earlier periods.
• Operating cash flow is strong at $408.2 million, supporting ongoing debt service and reinvestment.
• Liquidity is solid, with $2.87 billion in cash and short-term investments at quarter-end.
• Current assets exceed current liabilities, suggesting near-term obligations appear manageable.
• Gross profit remained robust at $934.8 million, showing the business still carries strong product economics.
• Non-cash amortization remains a large expense, reflecting the company’s acquisition-heavy history and depressing reported earnings quality.
• Share count has risen slightly over the last year, which can limit per-share growth if it continues.
• Debt is still high, with about $5.35 billion in total debt on the balance sheet.
• Intangibles and goodwill are very large, increasing the risk of future impairment charges if performance deteriorates.

Bottom line: Jazz Pharmaceuticals appears to be in a much better operating position than it was in mid-2025, with stronger sales, higher profits, and improved cash flow. However, investors should still watch leverage and acquisition-related intangibles closely, since those remain the main long-term risks on the balance sheet.